2021 CMSC Annual Meeting

Go back to the CMSC Education Website
Search

Tag: MSc

Sessions

December 1, 2021

LATE BREAKING SCIENCE

Progress in understanding and treating multiple sclerosis evolves continuously and not always on a schedule aligned with scientific meeting...

Read More →

Poster-Quality of Life and Outcomes

October 25, 2021

Understanding MS Symptoms and Impacts through Semi-Structured Interviews with Clinical Experts and People Living with MS

Background: Multiple sclerosis (MS) is a chronic progressive disease, affecting a broad range of important functions. In order to...

Read More →

Poster-Psychosocial Factors

October 25, 2021

Cognitive Fatigability and Cardiorespiratory Fitness in Persons with Advanced Multiple Sclerosis

Background: Fatigue, both physical and cognitive, is one of the most prevalent and disabling symptoms experienced by persons with multiple...

Read More →

Poster-Quality of Life and Outcomes

October 25, 2021

Direct Cost Associated with Multiple Sclerosis and Important Components; A Population-Based Study 1997-2017

Direct cost associated with Multiple sclerosis: A Population-Based Study 1997-2017 Background: Multiple sclerosis (MS) is a chronic...

Read More →

Poster-Multidisciplinary Care

October 25, 2021

Religiosity and Mental Health in Multiple Sclerosis

Background: People with Multiple Sclerosis (MS) often face the dysfunctions that accompany the disease, experiences that can lead to...

Read More →

Poster-Imaging

October 25, 2021

Neural Correlates of Hand Motor Function Revealed By Structural MR Imaging: A Smartphone-Based Remote Assessment Study in People with MS

Background: Regional gray matter pathology is associated with hand motor impairment in people with multiple sclerosis (PwMS). Objectives:...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Clinical Outcomes in Patients with COVID-19 Infection during Phase IV Studies of Cladribine Tablets for Treatment of Multiple Sclerosis

Background: The COVID-19 pandemic has become a significant concern for patients with multiple sclerosis (MS) and their healthcare...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Classic-MS: Long-Term Efficacy and Real-World Treatment Patterns for Patients with Relapsing Multiple Sclerosis Who Received Cladribine Tablets in Phase III Parent Trials

Background: CLASSIC-MS (NCT03961204) explores the long-term efficacy and durability of effect of cladribine tablets (CladT; cumulative dose...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Comparison of Therapy Selection Drivers within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment

Background: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with...

Read More →

Poster-Disease-modifying Therapy

October 25, 2021

Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study

Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...

Read More →
MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US
Facebook-f Twitter Linkedin Youtube

© 2021 CMSC